Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02793583
Title Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

diffuse large B-cell lymphoma

Therapies

Umbralisib

Ublituximab + Umbralisib

Age Groups: adult
Covered Countries USA


No variant requirements are available.